Anti-58K Golgi protein antibody [58K-9] - Golgi Marker
| Name | Anti-58K Golgi protein antibody [58K-9] - Golgi Marker |
|---|---|
| Supplier | Abcam |
| Catalog | ab27043 |
| Prices | $401.00 |
| Sizes | 200 µg |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | 58K-9 |
| Applications | WB FA FC ICC/IF ICC/IF |
| Species Reactivities | Rat, Hamster, Bovine, Dog, Human, Monkey, Monkey, Pig |
| Antigen | Full length native protein (purified) (Rat liver) |
| Description | Mouse Monoclonal |
| Gene | FTCD |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
![All lanes : Anti-58K Golgi protein antibody [58K-9] - Golgi Marker (ab27043) at 1 µg/mlLane 1 : Liver (Rat) Tissue Lysate, blocked with 5% BSA Lane 2 : Liver (Rat) Tissue Lysate, blocked with 3% MilkLysates/proteins at 20 µg per lane.SecondaryGoat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_1/548_58K-Golgi-protein-Primary-antibodies-ab27043-4.jpg)
All lanes : Anti-58K Golgi protein antibody [58K-9] - Golgi Marker (ab27043) at 1 µg/mlLane 1 : Liver (Rat) Tissue Lysate, blocked with 5% BSA Lane 2 : Liver (Rat) Tissue Lysate, blocked with 3% MilkLysates/proteins at 20 µg per lane.SecondaryGoat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.
ab27043 (1µg/ml, 5µg/ml and 10µg/ml) staining 58K Golgi protein in SK-N-SH cells (green). Cells were fixed in Methanol, permabilised using 0.5% Triton X100 in PBS and counterstained with DAPI in order to highlight the nucleus (red).
ICC/IF image of ab27043 stained human HeLa cells. The cells were methanol fixed (5 min) and incubated with the antibody (ab27043, 1µg/ml) for 1h at room temperature. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Image-iTTM FX Signal Enhancer was used as the primary blocking agent, 5% BSA (in TBS-T) was used for all other blocking steps. DAPI was used to stain the cell nuclei (blue). Alexa Fluor® 594 WGA was used to label plasma membranes (red).
![Overlay histogram showing HepG2 cells stained with ab27043 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab27043, 2µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_1/551_58K-Golgi-protein-Primary-antibodies-ab27043-10.jpg)
Overlay histogram showing HepG2 cells stained with ab27043 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab27043, 2µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
Product References
Bioengineering murine mastocytoma cells to produce anticoagulant heparin. - Bioengineering murine mastocytoma cells to produce anticoagulant heparin.
Gasimli L, Glass CA, Datta P, Yang B, Li G, Gemmill TR, Baik JY, Sharfstein ST, Esko JD, Linhardt RJ. Glycobiology. 2014 Mar;24(3):272-80.
KCNC3(R420H), a K(+) channel mutation causative in spinocerebellar ataxia 13 - KCNC3(R420H), a K(+) channel mutation causative in spinocerebellar ataxia 13
Gallego-Iradi C, Bickford JS, Khare S, Hall A, Nick JA, Salmasinia D, Wawrowsky K, Bannykh S, Huynh DP, Rincon-Limas DE, Pulst SM, Nick HS, Fernandez-Funez P, Waters MF. Neurobiol Dis. 2014 Nov;71:270-9.
Biophysical characterisation of calumenin as a charged F508del-CFTR folding - Biophysical characterisation of calumenin as a charged F508del-CFTR folding
Tripathi R, Benz N, Culleton B, Trouve P, Ferec C. PLoS One. 2014 Aug 13;9(8):e104970.
A trafficking-deficient mutant of KCC3 reveals dominant-negative effects on K-Cl - A trafficking-deficient mutant of KCC3 reveals dominant-negative effects on K-Cl
Ding J, Ponce-Coria J, Delpire E. PLoS One. 2013 Apr 4;8(4):e61112.
Secretory defect and cytotoxicity: the potential disease mechanisms for the - Secretory defect and cytotoxicity: the potential disease mechanisms for the
Li S, Yang Z, Hu J, Gordon WC, Bazan NG, Haas AL, Bok D, Jin M. J Biol Chem. 2013 Apr 19;288(16):11395-406.
Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic - Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic
Rodriguez D, Ramsay AJ, Quesada V, Garabaya C, Campo E, Freije JM, Lopez-Otin C. Hum Mol Genet. 2013 Jun 1;22(11):2273-82.
Autoregulation of connexin43 gap junction formation by internally translated - Autoregulation of connexin43 gap junction formation by internally translated
Smyth JW, Shaw RM. Cell Rep. 2013 Nov 14;5(3):611-8.
Atp6ap2/(pro)renin receptor interacts with Par3 as a cell polarity determinant - Atp6ap2/(pro)renin receptor interacts with Par3 as a cell polarity determinant
Kanda A, Noda K, Yuki K, Ozawa Y, Furukawa T, Ichihara A, Ishida S. J Neurosci. 2013 Dec 4;33(49):19341-51.
Key amino acid residues within the third membrane domains of NR1 and NR2 subunits - Key amino acid residues within the third membrane domains of NR1 and NR2 subunits
Kaniakova M, Krausova B, Vyklicky V, Korinek M, Lichnerova K, Vyklicky L, Horak M. J Biol Chem. 2012 Jul 27;287(31):26423-34.
Participation of the cell polarity protein PALS1 to T-cell receptor-mediated - Participation of the cell polarity protein PALS1 to T-cell receptor-mediated
Carvalho G, Poalas K, Demian C, Hatchi E, Vazquez A, Bidere N. PLoS One. 2011 Mar 30;6(3):e18159.